Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.65 |
| ▸ | HPGD | P15428 | 10/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.64 |
| ▸ | MGAM | O43451 | 1/20 | 0.64 |
| ▸ | SI | P14410 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decursinol Angelate SCHEMBL3901157 | 1.00 | MAOA (0.76) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| Decursinol Angelate SCHEMBL3901154 | 1.00 | MAOA (0.76) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| Decursinol Angelate SCHEMBL4740622 | 1.00 | MAOA (0.76) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| SCHEMBL14105695 | 0.90 | MAOA (0.73) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| SCHEMBL14303567 | 0.89 | MAOA (0.79) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| SCHEMBL4740846 | 0.89 | MAOA (0.79) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| SCHEMBL31046705 | 0.88 | MAOA (0.69) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| SCHEMBL31046691 | 0.88 | MAOA (0.69) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| Decursin SCHEMBL14511556 | 0.87 | MAOA (1.00) | MAOAKDM4EHPGDHSD17B10CYP3A4 | |
| Decursin SCHEMBL3904733 | 0.87 | MAOA (1.00) | MAOAKDM4EHPGDHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120082502-A | Method for differentiating pluripotent stem cells into insulin-secreting cells | 广西中医药大学附属瑞康医院（广西中西医结合医院） | 2025-06-03 | — | — | CN | claimed |
| US-20250000926-A1 | METHOD FOR PREVENTING, IMPROVING OR TREATING INFLAMMATORY SKIN DISEASE COMPRISING A COMPOSITION COMPRISING A FERMENTED ANGELICA GIGAS EXTRACT | SOOY-K CO., LTD. (KR) | 2025-01-02 | — | — | US | claimed |
| CN-118685346-A | Small molecule culture medium for liver organoid amplification and application thereof | 山东大学 | 2024-09-24 | — | — | CN | claimed |
| US-20240115678-A1 | PERSONALIZED MULTIDISCIPLINARY CANCER THERAPY | VELTMEYER JAMES (US) | 2024-04-11 | — | — | US | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230201215-A1 | DRUG COMBINATIONS FOR INHIBITING INFECTIVITY OF INFLUENZA AND CORONA VIRUSES | SYSTAMEDIC INC. (US) | 2023-06-29 | — | — | US | claimed |
| CN-113101308-B | Angelica gigas nakai extract and preparation method and application thereof | 吉林大学珠海学院 | 2022-09-13 | — | — | CN | claimed |
| CN-122005983-A | Loess cupping glass for medical use and preparation method thereof | 延边朝鲜族自治州朝医医院(延边朝鲜族自治州第二人民医院、延边朝鲜族自治州肿瘤医院) | 2026-05-12 | — | — | CN | disclosed |
| US-20260048093-A1 | COMBINATION THERAPY OF MIXED HERBAL EXTRACT AND DOCETAXEL FOR PREVENTING OR TREATING CANCER | JAEIN R&P INC. (KR) | 2026-02-19 | — | — | US | disclosed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250367229-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | MITOPOWER LLC (US) | 2025-12-04 | — | — | US | disclosed |
| CN-120082502-A | Method for differentiating pluripotent stem cells into insulin-secreting cells | 广西中医药大学附属瑞康医院（广西中西医结合医院） | 2025-06-03 | — | — | CN | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| CN-113101308-B | Angelica gigas nakai extract and preparation method and application thereof | 吉林大学珠海学院 | 2022-09-13 | — | — | CN | disclosed |
| CN-114668829-A | Radix stephaniae tetrandrae and radix astragali composition for inhibiting COX-2 activity and preparation method and application thereof | 北京尚捷优蓝科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022090819-A1 | NON-TOXIC FUROCOUMARIN-RICH PLANT EXTRACTS AND RELATED COMPOSITIONS FOR USE AS ANTIMICROBIAL SUBSTANCE OR MEDICAMENT AND OTHER THERAPEUTIC USES | ICE-P LIFE, S.L. (ES) | 2022-05-05 | — | — | WO | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | MITOPOWER LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MitoPower, LLC (US) | 2022-03-03 | — | — | US | disclosed |
| WO-2008004817-A1 | NOVEL DECURSIN DERIVATIVES AND THE USE THEREOF | PARK YONG JIN (KR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048093-A1 | COMBINATION THERAPY OF MIXED HERBAL EXTRACT AND DOCETAXEL FOR PREVENTING OR TREATING CANCER | EGFR, ERBB2, TTBK2 | MAOA 4425/4885KDM4E 3974/4885HPGD 4314/4885 |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | MAOA 486/4885KDM4E 3520/4885HPGD 134/4885 |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | NME4, NADK, NQO1 | MAOA 484/4885KDM4E 3963/4885HPGD 133/4885 |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | MAOA 471/4885KDM4E 1457/4885HPGD 1052/4885 |
| US-20250367229-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | NQO1, DOHH, DHODH | MAOA 1179/4885KDM4E 3542/4885HPGD 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.